Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’S Arixtra “Approvable” For Acute Coronary Syndromes

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm is seeking FDA approval of fondaparinux for treatment of unstable angina or non-ST segment elevation myocardial infarction and ST-segment elevation MI.
Advertisement

Related Content

Lovenox Clears FDA For STEMI After Priority Review
Lovenox Clears FDA For STEMI After Priority Review
Sanofi-Aventis' Lovenox sNDA Granted Priority Review
Sanofi-Aventis' Lovenox sNDA Granted Priority Review
Bayer/J&J Plan Rivaroxaban Filing For Chronic Indications In 2010
GSK’s Arixtra Acute Coronary Syndrome Indication Gets Priority Review
GSK’s Arixtra Acute Coronary Syndrome Indication Gets Priority Review

Topics

Advertisement
UsernamePublicRestriction

Register

PS065647

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel